Overexpression of Macrophage Migration Inhibitory Factor and Its Homologue D-Dopachrome Tautomerase as Negative Prognostic Factor in Neuroblastoma
Authors:
- Eugenio CavalliECEugenio Cavalli
- Emanuela MazzonEMEmanuela Mazzon
- Santa MammanaSMSanta Mammana
- Maria Sofia BasileMBMaria Sofia Basile
- Salvo Danilo LombardoSLSalvo Danilo Lombardo
- Katia ManganoKMKatia Mangano
- Placido BramantiPBPlacido Bramanti
- Ferdinando NicolettiFerdinando Nicoletti
- Paolo FagonePaolo Fagone
- Maria Cristina PetraliaMPMaria Cristina Petralia
Open Access
- 19 October 2019
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 9 (10) , 284
Abstract
Neuroblastoma (NB) represents one of the most frequent pediatric solid tumors. Macrophage migration inhibitory factor (MIF) is a cytokine exerting multiple biological functions. More recently, a second member of the MIF family of cytokine has been identified, the D-dopachrome tautomerase (DDT), that exerts several overlapping functions with MIF. Growing evidence suggests a key role for MIF and DDT in the development of cancer. The aim of this study is to characterize the prognostic value of MIF and DDT in NB. We show that higher expression levels of MIF and DDT in Stage 4 NB samples are associated with a poorer prognosis, independently of the presence of MYCN amplification. Moreover, higher levels of MIF are mostly enriched by Th1 cells, while lower levels of MIF are associated with an increased proportion of B cells, Cytotoxic T cells, Dendritic cells and Natural Killer T cells. We also show that treatment with the histone deacetylase (HDAC) inhibitor, vorinostat, of the NB cell line, SH-SY5Y, determines a significant reduction in the expression of both MIF and DDT. Finally, MIF and DDT inhibition by short interfering RNA is able to revert vincristine sensitivity in vitro. Overall, our data suggest that MIF exert pro-tumorigenic properties in NB, likely by dampening antigen presentation and cytotoxic immune responses, and we propose the HDAC inhibitors as a potential therapeutic strategy for NB patients.Keywords
Funding Information
- IRCCS “Centro Neurolesi Bonino-Pulejo” (current research funds 2019)
This publication has 78 references indexed in Scilit:
- FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastomaOncogene, 2019
- Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGFJournal of Neuroimmunology, 2019
- KCNMA1 Expression Is Downregulated in Colorectal Cancer via Epigenetic MechanismsCancers, 2019
- Involvement of the Nrf2/HO‐1/CO axis and therapeutic intervention with the CO‐releasing molecule CORM‐A1, in a murine model of autoimmune hepatitisJournal of Cellular Physiology, 2017
- Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic reviewHead & Neck, 2017
- Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targetsOncology Letters, 2016
- Targeting distinct tautomerase sites of D‐DT and MIF with a single molecule for inhibition of neutrophil lung recruitmentThe FASEB Journal, 2014
- Neuroblastoma and MYCNCold Spring Harbor Perspectives in Medicine, 2013
- Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer CellsNeoplasia, 2010
- Involvement of Macrophage Migration Inhibitory Factor (MIF) in the Mechanism of Tumor Cell GrowthMolecular Medicine, 1998